메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection

SHANGHAI, Oct. 30, 2025 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's previous experience and knowledge in development of RSV therapeutics, this milestone marks a major step forward in RSV prevention and enriches the company's innovative anti-RSV drug portfolio. The multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase II study wil
- 김갑성 기자
- 2025-10-30 09:00
Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.

BEIJING, Oct. 30, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the Company's diversified and high-potential multi-product portfolio, at TCT 2025 in the U.S.. 6-Month Follow-up Results of LuX-Valve Plus TRINITY Study-Released by Prof.
- 김갑성 기자
- 2025-10-30 09:00
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development

-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese (DIO) rat study. -ASC36 has excellent chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation with other peptides including ASC35, a GLP-1R/GIPR dual agonist. -Submission of an Investi
- 김갑성 기자
- 2025-10-30 08:10
색상 측정 분야를 혁신할 헌터랩 Agera L2, 11월 공식 출시

레스턴, 버지니아주, 2025년 10월 30일 -- 색상 측정 분야가 일대 혁신을 앞두고 있다. 헌터랩(HunterLab)이 11월 혁신적인 차세대 분광광도계(spectrophotometric) 제품 Agera L2를 공개한다. Agera L2는 전 세계의 색상 측정과 인식 방식을 새롭게 정의할 예정이다. Agera L2는 계측적 색상 측정과 인간의 눈이 색상을 인지하는 방식을 일치시키려는 헌터랩의 지속적인 노력이 이뤄낸 중대한 진전이다. 정밀성, 속도, 사용성을 종합적으로 고려해 설계된 이 제품은 계산된 색상 값과 시각적 평가 사이의 격차를 해소하는 기술을 도입했다. 핵심 기술은 자연광을 완벽하게 재현한 광원인 True D65 일광 조명이다. 이러한 기술적 발전 덕분에 사용자는 실제 일광 조건에서 보는 그대로 색상을 측정할 수 있다. 실험실에서 측정하는 높은 정밀성과 실제 환경에서 인간의 눈으로 인지하는 색상이 이제 하나의 기기 안에서 일치하게 된 것이다. Agera L2는 UltraDark 성능(극도로 낮은 밝기 측정 성능)과 결합되어 가장 어둡고 빛을 많이 흡수하는 소재에서도 뛰어난 정확도를 보여준다. 또한 이
- 김갑성 기자
- 2025-10-30 08:00
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study

- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL, Switzerland, Oct. 29, 2025 -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and Professor Karl Wagner from the University of Bonn, announce the results of new research confirming Jungbunzlauer's tricalcium citrate (TCC TB) sets a new standard for direct compression in pharmaceutical and nutraceutical tablet manufacturing. "This collaboration with Professor Wa
- 김갑성 기자
- 2025-10-29 23:21
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with the new hub-and-spoke business model, the Company has formed a new subsidiary, Visara, Inc. (Visara), which acquired VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2 that could potentially provide more eff
- 김갑성 기자
- 2025-10-29 23:15
NABR: 긴꼬리원숭이 개체수를 새로 검토한 끝에 전 세계 개체수를 정확히 파악할 두 가지 권고안 제시

워싱턴, 2025년 10월 29일 -- 미국 영장류학회지(American Journal of Primatology)에 최근 게재된 한 논문은 긴꼬리원숭이(Macaca fascicularis)와 관련해 국제자연보전연맹(IUCN)이 내린 결정의 근거가 된 연구 결과를 비판했다. '널리 분포한 영장류의 개체수 추산(Estimating the Abundance of Widely Distributed Primates)'이라는 제목의 이 논문은 IUCN이 채택한 과학적 연구 결과는 "허점을 안고 있어서 영장류의 전 세계 개체수를 턱없이 적게 추정하는 문제를 초래한다"고 결론지었다. 또한 이 논문은 이러한 개체수가 "서식지 적합성과 개체 밀도 간의 전혀 현실적이지 않은 상관관계"를 근거로 추산되었다고 주장했다. 해당 기사는 https://onlinelibrary.wiley.com/doi/full/10.1002/ajp.70082에서 확인할 수 있다. 미국 영장류학회지는 미국영장류학회(American Society of Primatologists)에서 공식적으로 발간하는 학술지이다. 미국영장류학회의
- 김갑성 기자
- 2025-10-29 22:12
Suvoda launches unified patient app to reduce logistical challenges for clinical trial participants

CONSHOHOCKEN, Pa., Oct. 29, 2025 -- Suvoda (recently merged under common ownership with Greenphire), a global clinical trial technology company specializing in software solutions to address trial complexity in mission-critical, time-sensitive moments, today announced the release of its unified patient mobile app. The Suvoda app is a single, intuitive experience that will bring visit scheduling, questionnaires, travel information, receipt submission, and reimbursement tracking into one place to reduce the logistical burden for clinical trial participants. The new patient app com
- 김갑성 기자
- 2025-10-29 21:15
ICHORtec and Johns Hopkins University Expand Collaboration to Enhance CRISPR Gene Editing Specificity Using Quantum FMB® Technology

BERLIN and BALTIMORE, Oct. 29, 2025 -- ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School of Medicine. This partnership, aligned with the International Year of Quantum Science and Technology (IYQ) 2025, leverages ICHORtec's proprietary Quantum Fluorimetry of Molecular Binding (Q-FMB®) technology to advance the precision of CRISPR guide RNA (gRNA) design and evaluation, minimizing off-target effects in gene editing therapies. The collabo
- 김갑성 기자
- 2025-10-29 21:00
Study Finds ELISAs in Milk Samples Less Reliable for Johne's Disease Detection -- $198M in Dairy Losses Underscore Need for More Accurate Milk Testing

Peer-reviewed (in-press) study finds serum-based antibody tests align, but milk results vary—calling for improved milk-specific diagnostics to strengthen herd surveillance and profitability CARLSBAD, Calif., Oct. 29, 2025 -- Pictor Holdings Inc. today announced new peer-reviewed data showing close agreement between commercial antibody tests when used on serum, but higher variability when used on milk—findings that highlight the need for milk-specific diagnostic standards to scale Johne's disease surveillance. Johne's disease costs the U.S. dairy industry an estimated $19
- 김갑성 기자
- 2025-10-29 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분